首页> 外文期刊>British Journal of Obstetrics and Gynaecology >A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis.
【24h】

A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis.

机译:与有症状子宫内膜异位症保守手术后的预期处理相比,促性腺激素释放激素激动剂的疗效更高。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: To ascertain whether the frequency of pelvic pain recurrence is reduced and time to symptoms recurrence is prolonged in women with symptomatic endometriosis undergoing conservative surgery and post-operative hormonal therapy compared with women treated with surgery only. Pregnancy rates and time to conception in women wanting children were also evaluated. DESIGN: A multicentre, prospective, randomised controlled study. SETTING: Nineteen Italian academic departments and teaching hospitals specialising in reparative and reconstructive surgery. POPULATION: A total of 269 women undergoing conservative surgery for mild to severe symptomatic endometriosis. METHODS: After surgery the women were assigned to treatment with subcutaneous goserelin depot injections for six months or to expectant management. Dysmenorrhoea, deep dyspareunia, nonmenstrual pain and general discomfort were graded according to a verbal rating scale from 0 (absent) to 3 (severe) and the scores summed to give a total symptoms score. Only patients with at least one preoperative moderate or severe symptom were enrolled. The women were evaluated regularly for two years. MAIN OUTCOME MEASURES: Post-operative pain recurrences (total symptoms scores > or = 5), time to recurrence, pregnancy rates and time to conception in the two study groups. RESULTS: At one- and two-year follow up visits, 14/107 (13.1%) and 19/81 (23.5%) patients had moderate or severe symptoms recurrence in the goserelin group compared with, respectively, 22/103 (21.4%) and 27/74 (36.5%) in the expectant management group (P = 0.143 at 1 year and 0.082 at 2 years). Time to symptoms recurrence was significantly longer in the goserelin group according to survival analysis (Wilcoxon test, P = 0.041). Among women wanting children, few conceptions occurred in both the goserelin (8/69, 11.6%) and the expectant management group (14/76, 18.4%). There was no significant difference at survival analysis (Wilcoxon test, P = 0.427). CONCLUSION: Post-operative treatment with goserelin significantly prolonged the pain-free interval after conservative surgery for symptomatic endometriosis and did not influence reproductive prognosis.
机译:目的:与仅接受手术治疗的女性相比,确定有症状的子宫内膜异位症接受保守手术和术后激素治疗的女性,盆腔痛复发的频率是否减少,症状复发的时间是否延长。还评估了想要孩子的妇女的怀孕率和怀孕时间。设计:一项多中心,前瞻性,随机对照研究。地点:19个意大利的学术部门和教学医院专门从事修复和重建手术。人口:共有269名因轻度至严重症状性子宫内膜异位症接受保守手术的妇女。方法:妇女在手术后被分配皮下注射戈舍瑞林贮库注射治疗六个月或进行预期治疗。痛经,深层痛经,非经痛和一般不适根据语言评分等级从0(不存在)到3(严重)进行分级,总分得出总的症状评分。仅招募具有至少一种术前中度或严重症状的患者。定期对妇女进行评估,为期两年。主要观察指标:两个研究组的术后疼痛复发(症状总分≥5),复发时间,妊娠率和受孕时间。结果:在一年和两年的随访中,戈舍瑞林组分别有14/107(13.1%)和19/81(23.5%)患者出现中度或重度症状复发,而分别为22/103(21.4%) )和预期管理组的27/74(36.5%)(1年时P = 0.143,2年时0.082)。根据生存分析(Golcoxon检验,P = 0.041),戈舍瑞林组的症状复发时间明显更长。在想要孩子的妇女中,戈舍瑞林(8 / 69,11.6%)和待产管理组(14 / 76,18.4%)的受孕率均很少。生存分析无显着差异(Wilcoxon检验,P = 0.427)。结论:戈舍瑞林的术后治疗显着延长了有症状子宫内膜异位症保守手术后的无痛间隔时间,并且不影响生殖预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号